GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » EBIT

Huadong Medicine Co (SZSE:000963) EBIT : ¥3,692 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co EBIT?

Huadong Medicine Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥1,091 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥3,692 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Huadong Medicine Co's annualized ROC % for the quarter that ended in Mar. 2024 was 17.75%. Huadong Medicine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 49.86%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Huadong Medicine Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.92%.


Huadong Medicine Co EBIT Historical Data

The historical data trend for Huadong Medicine Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co EBIT Chart

Huadong Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,577.46 3,522.03 2,900.03 3,156.23 3,584.20

Huadong Medicine Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 983.75 860.96 927.72 811.77 1,091.24

Competitive Comparison of Huadong Medicine Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Huadong Medicine Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huadong Medicine Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huadong Medicine Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Huadong Medicine Co's EV-to-EBIT falls into.



Huadong Medicine Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,692 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huadong Medicine Co  (SZSE:000963) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Huadong Medicine Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=4501.272 * ( 1 - 19.47% )/( (19376.575 + 21468.207)/ 2 )
=3624.8743416/20422.391
=17.75 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=33509.362 - 9469.409 - ( 4663.378 - max(0, 10802.606 - 18496.68+4663.378))
=19376.575

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=34467.844 - 9436.572 - ( 3563.065 - max(0, 10918.318 - 19212.283+3563.065))
=21468.207

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Huadong Medicine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=4364.956/( ( (5204.467 + max(2480.106, 0)) + (5116.938 + max(4706.817, 0)) )/ 2 )
=4364.956/( ( 7684.573 + 9823.755 )/ 2 )
=4364.956/8754.164
=49.86 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7455.251 + 4290.214 + 355.524) - (9469.409 + 0 + 151.474)
=2480.106

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9677.692 + 4224.075 + 430.357) - (9436.572 + 0 + 188.735)
=4706.817

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Huadong Medicine Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=3691.694/53365.591
=6.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huadong Medicine Co EBIT Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Huadong Medicine Co (SZSE:000963) Business Description

Traded in Other Exchanges
N/A
Address
468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.
Executives
He Ru Fen Supervisors
Hu Bao Zhen Supervisors
Zhou Shun Hua Executives
Shao Ling Min Supervisors
Wan Ling Ling Executives
Fu Hang Director
Yue Jin Director
Chen Bo Secretary Dong
Qin Yun Supervisors
Li Bang Liang Directors, executives
Zhou Jin Bao Directors, executives

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines